Clinical Biomarkers Forum
Prague, Czech Republic (September 13-14, 2007)
Our expert panel of speakers, includes representatives from: F. Hoffmann-La Roche, Pfizer, Wyeth, AstraZeneca, UCB, Bayer, Merck Serono, Abbott, Health Discovery Corporation, and many more…
Delegates already attending have brought their queries to the table, and will benefit from case study presentations and roundtable discussions on:
- Maximising the potential of biomarkers across drug development
- How companies have lowered attrition, risk and costs
- Development of surrogate biomarkers and companion diagnostics for the pharmaceutical industry
- How can we translate pre-clinical results into humans?
- Have companies seen a real reduction in timeframes as a direct result of biomarker implementation?
- When will regulations catch up with innovation?....And much more!
What is your number one concern or question relating to the performance of biomarkers in R&D? Make sure that it is raised and answered at this unique event by registering today.
To register, click here or alternatively email paul_osmond(at)osneymedia.co.uk for an event PDF. (Reference 930GTB)
More: http://www.clinicalbiomarkers.net/event_view_link.asp?eid=125
